BlogNovember 18, 2026
Market Spotlight: PE bets big on European healthcare
Highlights
- Private equity is turning to healthcare for resilient earnings and long-term demand
- Major healthcare M&A deals, including the €10.8bn Qiagen and €10.9bn Recordati bids, signal strong PE appetite
- Attractive valuations and defensive growth could drive further healthcare M&A opportunities across Europe
European private equity dealmakers, sitting on near record levels of dry powder, are under pressure to deploy capital. In uncertain markets, healthcare is proving a reliable release valve.
At the end of October, Swedish buyout firm EQT agreed a €10.8 billion deal to take German diagnostics group Qiagen private. The deal is one of the largest buyout-backed European take privates in the past five years, and comes just months after another private equity firm, CVC, led a €10.9 billion bid to take Italian pharmaceutical company Recordati private.
A steady option in unsteady times
Healthcare has been a favourite for European private equity investors for several years. Europe’s ageing population (more than one in five people in Europe are 65 or older, and the 80-and-over age group is the fastest growing) ensures long-term, non-cyclical demand for healthcare and medicines, and businesses in the sector are typically characterised by steady earnings and lower volatility through downturns.
These are attractive attributes at any point in the capital cycle, but especially in the current context of elevated energy prices, sticky inflation and geopolitical instability.
Healthcare deals are becoming an even more important deployment channel as the software sector, once a tried and trusted channel for private equity investment, faces disruption and an uncertain growth path following the release of AI-powered tools that enable users to replicate software functions at significantly lower development costs.
Appealing entry points
Pharma, medical and biotech (PMB) only ranked as the fifth most active sector in the EMEA region by deal value in Q3 2026, according to Datasite’s most recent EMEA Deal Drivers report, behind financial services, TMT, industrials & chemicals, and energy, mining and utilities.
What the headline figures don’t fully reveal are the drivers of activity in sectors that rank above PMB. In the industrials and chemicals sector, activity has been shaped by a combination of defensive consolidation and, in some cases restructurings, while financial services value has been boosted by two mega-deals in the Italian banking market and energy, mining, and utilities activity has concentrated in the Gulf.
TMT activity, meanwhile, has been driven by the AI buildout, a trade that private equity firms continue to pursue, but with more caution, as public frustration with data centres and concerns around valuations and debt levels grow.
Healthcare assets, by contrast, promise greater stability, as well as the opportunity to invest at attractive price points.
Prior to the EQT bid, for example, Qiagen’s share price had more than halved in the five-year period between 2021 and 2026 as demand for its Covid and tuberculosis tests slowed. Recordati’s closing share price prior to the CVC bid, meanwhile, was 13% below CVC’s offer price.
Buyout firms see opportunities to acquire healthcare assets at attractive prices, and grow earnings by allowing management teams to focus resources on the most lucrative business lines in a private setting, away from the pressures of public market scrutiny.
With capital to invest, and the clock ticking to invest it, there could be more deals like Qiagen and Recordati to come, as buyout firms scan markets for assets that provide stable earnings and downside protection.
Keep updated
with us
Sign up for newsletter
Get the latest updates and insights from Datasite delivered to your inbox.


